{"id":675068,"date":"2026-05-31T00:53:15","date_gmt":"2026-05-31T00:53:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/675068\/"},"modified":"2026-05-31T00:53:15","modified_gmt":"2026-05-31T00:53:15","slug":"revolution-medicines-starts-early-access-for-pancreatic-cancer-drug","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/675068\/","title":{"rendered":"Revolution Medicines starts early access for pancreatic cancer drug"},"content":{"rendered":"<p class=\"author-bio\">Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout Loud<\/a> and author of the newsletter <a href=\"https:\/\/www.statnews.com\/signup\/scorecard\/\" rel=\"nofollow noopener\" target=\"_blank\">Adam\u2019s Biotech Scorecard.<\/a> You can reach Adam on Signal at stataf.54.<\/p>\n<p>CHICAGO \u2014 The biotech company Revolution Medicines has begun sending its experimental, life-extending treatment for pancreatic cancer to physicians and their patients under an early access program authorized by the Food and Drug Administration, the company\u2019s CEO, Mark Goldsmith, told STAT.<\/p>\n<p>\u201cWe are now shipping the drug,\u201d he said, speaking Friday evening at a <a href=\"https:\/\/www.statnews.com\/event\/stat-at-asco-2026\/\" rel=\"nofollow noopener\" target=\"_blank\">STAT event<\/a> held in conjunction with the annual meeting of the American Society of Clinical Oncology.\u00a0<\/p>\n<p>The drug, daraxonrasib, is not yet approved. But patients with pancreatic cancer have been clamoring for it since mid-April, when Revolution reported the <a href=\"https:\/\/www.statnews.com\/2026\/04\/13\/revolution-medicines-successful-treatment-pancreatic-cancer-daily-pill\/\" rel=\"nofollow noopener\" target=\"_blank\">striking results of a Phase 3 clinical trial<\/a>. Patients treated with daraxonrasib lived nearly twice as long as patients offered standard chemotherapy \u2014 an outcome unprecedented in the pancreatic cancer field.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/12\/1765280600_844_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall&hellip;\n","protected":false},"author":2,"featured_media":675069,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[294357,10743,28,687,245,246,247,248],"class_list":["post-675068","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-asco","tag-biotech","tag-business","tag-cancer","tag-drug-development","tag-fda","tag-pharmaceuticals","tag-stat"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/675068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=675068"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/675068\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/675069"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=675068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=675068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=675068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}